Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost

PURPOSE: Efficacy, tolerability and safety of the novel preservative-free prostaglandin tafluprost 0.0015% were investigated for the treatment of patients with glaucoma or ocular hypertension in a clinical setting. PATIENTS AND METHODS: Data were collected in a non-interventional, prospective, multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hommer, Anton, Kimmich, Friedemann
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104790/
https://www.ncbi.nlm.nih.gov/pubmed/21629567
http://dx.doi.org/10.2147/OPTH.S17876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104790/
https://www.ncbi.nlm.nih.gov/pubmed/21629567
http://dx.doi.org/10.2147/OPTH.S17876

Ejemplares similares